These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32442617)

  • 1. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence.
    Mitchell KG; Parra ER; Zhang J; Nelson DB; Corsini EM; Villalobos P; Moran CA; Skoulidis F; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    Ann Thorac Surg; 2020 Oct; 110(4):1131-1138. PubMed ID: 32442617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Oudart JB; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 4. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
    Chen L; Engel BE; Welsh EA; Yoder SJ; Brantley SG; Chen DT; Beg AA; Cao C; Kaye FJ; Haura EB; Schabath MB; Cress WD
    J Thorac Oncol; 2016 Jun; 11(6):838-49. PubMed ID: 26917230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
    J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells.
    Nishimura S; Yashiro M; Sera T; Yamamoto Y; Kushitani Y; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Okuno T; Murakami Y; Ohira M
    Carcinogenesis; 2020 Nov; 41(11):1616-1623. PubMed ID: 32236518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pons-Tostivint E; Lugat A; Fontenau JF; Denis MG; Bennouna J
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
    Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
    Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
    Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer.
    Liu S; Miao Y; Fan C; Liu Y; Yu J; Zhang Y; Dai S; Wang E
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):334-40. PubMed ID: 23235348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.
    Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M
    In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.
    Wang H; Guo J; Shang X; Wang Z
    Int Immunopharmacol; 2020 Jul; 84():106574. PubMed ID: 32413741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
    Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
    Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases.
    Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
    J Thorac Oncol; 2015 Mar; 10(3):531-4. PubMed ID: 25695224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
    Chen YY; Huang YJ; Huang HK; Chang H; Lee SC; Shieh YS; Huang TW
    J Cancer Res Clin Oncol; 2020 May; 146(5):1299-1306. PubMed ID: 32107626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.